Background: Complete reporting of seroepidemiologic studies is paramount to inform public health decision-making. The Reporting of Seroepidemiologic studies-SARS-CoV-2 (ROSES-S) guideline is a checklist that guides the reporting of SARS-CoV-2 seroepidemiological studies. Adherence of SARS-CoV-2 seroepidemiologic studies to the ROSES-S guideline has not yet been evaluated. Objectives: Evaluate SARS-CoV-2 seroepidemiologic study reporting by assessing adherence to the ROSES-S reporting guideline; determine whether publication of the ROSES-S guideline was associated with reporting completeness; and identify study characteristics associated with reporting completeness. Methods: A stratified random sample of SARS-CoV-2 seroepidemiologic studies was evaluated for adherence to the ROSES-S guideline. Study adherence to each reporting item was categorized as "reported", "not reported", or "not applicable". Percent adherence per reporting item and the median and interquartile range (IQR) adherence were reported across all items and by item domain. Beta regression analyses examined if study characteristics were associated with changes in the overall adherence scores. Results: 199 studies were analyzed. Median adherence to reporting items was 48.1% (IQR 40.0%-55.2%) per study, with no significant changes before and after guideline publication. Article publication source (p<0.001), study risk of bias (p=0.001), and sampling method (p=0.004) were associated with adherence to the ROSES-S guideline. Conclusions: There was suboptimal reporting in SARS-CoV-2 seroepidemiologic studies, which was associated with key study characteristics. Publication of the ROSES-S guideline was not associated with changes in reporting practices. Given the importance of complete reporting for the utility of seroprevalence data, authors should improve reporting.

No abstract

Aim: To examine trends in basal insulin prescribing in older adults with chronic kidney disease (CKD). Materials and Methods:We conducted a population-based study of adults aged 66 years or older with treated diabetes from 1 January 2010 to 30 September 2020 in Ontario, Canada. We examined prevalent and incident prescriptions for human NPH, Levemir, glargine-100, Basaglar, glargine-300, and degludec insulin over 43 study intervals. We present trends in those with CKD, and in a subgroup, by estimated glomerular filtration rate (eGFR). To provide context for prescribing, we provide demographics, co-morbidities, and the healthcare utilization of included patients. Results:In CKD, use of basal insulin was about 2-fold higher than in the general treated diabetes cohort. Prescriptions for NPH declined over time, while prescriptions for Levemir and glargine-100 increased until 2018 then decreased. Following drug formulary approval (September 2018), prescriptions for glargine-300 and degludec increased substantially. Incident prescriptions for basal insulin in CKD declined over time; however, in those with an eGFR of less than 30 ml/min/1.73m 2 , rates remained stable. In recent years, rates of degludec and glargine-300 have rivalled glargine-100. Conclusions:In an era of new oral and injectable diabetes medications, the use of basal insulin has declined in older adults with CKD. However, in those with more advanced CKD, basal insulin, particularly newer analogues, remain a mainstay treatment.